公开(公告)号：US20240327393A1

公开(公告)日：2024-10-03

申请号：US18574309

申请日：2022-07-08

申请人： SIRONAX LTD.

发明人： Jianguang HAN ,  Zhiyuan ZHANG ,  Weijie HOU ,  Yimin JIANG ,  Yanping XU

IPC分类号： C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

CPC分类号： C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

摘要： Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

公开(公告)号：US20240325326A1

公开(公告)日：2024-10-03

申请号：US18583392

申请日：2024-02-21

申请人： University of Kentucky Research Foundation

发明人： Matthew S. Gentry ,  Ramon C. Sun ,  Ronald C Bruntz ,  Christopher M Waters

IPC分类号： A61K31/167 ,  A61K31/166 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/428 ,  A61K31/433 ,  A61K31/436 ,  A61K31/47 ,  A61K31/5375 ,  A61P11/00

CPC分类号： A61K31/167 ,  A61K31/166 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/428 ,  A61K31/433 ,  A61K31/436 ,  A61K31/47 ,  A61K31/5375 ,  A61P11/00 ,  C07K2317/569

摘要： A method for treating pulmonary fibrosis (PF) is provided. The method includes administering to a subject in need thereof an effective amount of a compound selected from the group consisting of a glycogen phosphatase inhibitor, an acid alpha-glucosidase (GAA) inhibitor, a glycogen synthase (GYS) inhibitor, a glycogen phosphorylase (GP) inhibitor, and combinations thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12102623B2

公开(公告)日：2024-10-01

申请号：US17932982

申请日：2022-09-16

申请人： THE GEORGE INSTITUTE FOR GLOBAL HEALTH

发明人： Anthony Rodgers ,  Stephen MacMahon

IPC分类号： A61K31/4422 ,  A61K31/277 ,  A61K31/382 ,  A61K31/40 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4418 ,  A61K31/495 ,  A61K31/517 ,  A61K31/549 ,  A61K31/554 ,  A61P9/12

CPC分类号： A61K31/4422 ,  A61K31/277 ,  A61K31/382 ,  A61K31/40 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4418 ,  A61K31/495 ,  A61K31/517 ,  A61K31/549 ,  A61K31/554 ,  A61P9/12 ,  A61K31/517 ,  A61K2300/00 ,  A61K31/4035 ,  A61K2300/00 ,  A61K31/382 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/4422 ,  A61K2300/00 ,  A61K31/554 ,  A61K2300/00 ,  A61K31/277 ,  A61K2300/00 ,  A61K31/40 ,  A61K2300/00 ,  A61K31/495 ,  A61K2300/00 ,  A61K31/4184 ,  A61K2300/00 ,  A61K31/4178 ,  A61K2300/00 ,  A61K31/41 ,  A61K2300/00

摘要： Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

公开(公告)号：US20240316008A1

公开(公告)日：2024-09-26

申请号：US18003153

申请日：2021-06-21

申请人： TRANQUIS THERAPEUTICS, INC.

发明人： Sanjay Kumar KAKKAR

IPC分类号： A61K31/4184 ,  A61P37/06

CPC分类号： A61K31/4184 ,  A61P37/06

摘要： The disclosure provides methods of treating a patient who has, or who is at risk for developing, systemic immune activation, including cytokine release syndrome (CRS) and sepsis. The method comprises administering a therapeutically effective amount of a compound of Formula I the patient.

公开(公告)号：US20240299362A1

公开(公告)日：2024-09-12

申请号：US18413659

申请日：2024-01-16

申请人： University of Ottawa

发明人： Derrick GIBBINGS

IPC分类号： A61K31/4184 ,  A61K9/00 ,  A61K31/167 ,  A61K31/403 ,  A61K31/4196 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61P31/10 ,  A61P33/06 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18

CPC分类号： A61K31/4184 ,  A61K9/0014 ,  A61K31/167 ,  A61K31/403 ,  A61K31/4196 ,  A61K38/17 ,  A61K38/1787 ,  A61K39/3955 ,  A61K45/06 ,  A61P31/10 ,  A61P33/06 ,  C07K14/47 ,  C07K14/70571 ,  C07K16/18 ,  C07K2317/622 ,  C07K2319/33

摘要： Provided herein are fusion constructs including a biologically active agent such as an antibody or derivative thereof which is functionally linked with a functional moiety such as an LC3 protein or portion thereof. Also provided are compositions and exosomes including such constructs, as well as methods for preparing exosomes containing such constructs, and methods for delivering such constructs to cells. Methods and uses of such constructs and exosomes for treating diseases or disorders are also provided, in which the constructs trigger autophagy of disease-related cellular or cytoplasmic targets such as misfolded/aggregated proteins in neurodegenerative diseases, for example.

公开(公告)号：US12076401B2

公开(公告)日：2024-09-03

申请号：US17110008

申请日：2020-12-02

申请人： TRANSLATIONAL DRUG DEVELOPMENT, LLC

发明人： Tong Wang ,  Stephen Gately ,  Paul Gonzales

IPC分类号： C07D401/04 ,  A61K31/4184 ,  A61K39/395 ,  A61K45/06 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  A61P35/04 ,  C07D235/30 ,  C07D403/04 ,  C07K16/28 ,  A61K31/7068 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K31/4184 ,  A61K45/06 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  A61P35/04 ,  C07D235/30 ,  C07D401/04 ,  C07D403/04 ,  C07K16/2818 ,  A61K31/7068 ,  A61K2039/507 ,  A61K2300/00 ,  C07K2317/76 ,  A61K31/4184 ,  A61K2300/00 ,  A61K39/3955 ,  A61K2300/00

摘要： The present invention describes compositions, including pharmaceutical compositions, comprising a PD-1 axis binding antagonist, a CTLA4 antagonist, a DNA demethylating agent, and/or an agent that binds members of the TNFRSF and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.

公开(公告)号：US20240270720A1

公开(公告)日：2024-08-15

申请号：US18576535

申请日：2022-07-11

申请人： INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS

发明人： Jung Mi HAH ,  Da Seul IM

IPC分类号： C07D403/04 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

CPC分类号： C07D403/04 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

摘要： Disclosed herein are an indazole yl benzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing, relieving or treating a protein kinase-related disease, including the derivative or the salt as an active ingredient, and the like. Further disclosed herein is a method for preventing or treating cancers, inflammatory diseases, or osteoporosis including administering the indazole yl benzimidazole derivative. The indazole yl benzimidazole derivative selectively inhibits Fms-like tyrosine kinase 3 (FLT3) when administered to a subject, and thus may be utilized for preventing, relieving or treating cancers including leukemia, inflammatory diseases including arthritis, or osteoporosis.

公开(公告)号：US12060615B2

公开(公告)日：2024-08-13

申请号：US16285019

申请日：2019-02-25

申请人： The Johns Hopkins University

发明人： William G. Nelson ,  Srinivasan Yegnasubramanian ,  Xiaohui Lin ,  Traci J. Speed ,  Zachery Reichert

IPC分类号： A61K31/4184 ,  A61K31/136 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/517 ,  A61K31/519 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/68

CPC分类号： C12Q1/6886 ,  A61K31/136 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/517 ,  A61K31/519 ,  G01N33/5011 ,  G01N33/6875 ,  C12Q2600/136 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N2500/00

摘要： The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.

公开(公告)号：US20240261245A1

公开(公告)日：2024-08-08

申请号：US18530612

申请日：2023-12-06

申请人： New York University ,  Massachusetts Institute of Technology

发明人： Thales PAPAGIANNAKOPOULOS ,  Tyler JACKS ,  Rodrigo ROMERO

IPC分类号： A61K31/198 ,  A61K31/282 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/655 ,  A61K31/675 ,  A61K33/243 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K38/50 ,  A61P35/04

CPC分类号： A61K31/198 ,  A61K31/282 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/655 ,  A61K31/675 ,  A61K33/243 ,  A61K38/191 ,  A61K38/193 ,  A61K38/20 ,  A61K38/21 ,  A61K38/50 ,  A61P35/04

摘要： The present disclosure relates to a method of treating a subject having cancer that includes selecting a subject having cancer associated with a deregulated NRF2/KEAP1 pathway and administering to the selected subject one or more inhibitors comprising a glutamine transporter inhibitor, a GPD2 inhibitor, or combination(s) thereof.

公开(公告)号：US20240247266A1

公开(公告)日：2024-07-25

申请号：US18542950

申请日：2023-12-18

申请人： Alnylam Pharmaceuticals, Inc.

发明人： Stephen Albert Huang ,  Kenji P. Fujita ,  Kang Lin ,  Nitin Mehrotra ,  Gabriel Robbie ,  Jongtae Lee ,  Sagar Agarwal

IPC分类号： C12N15/113 ,  A61K31/4184 ,  A61K31/713 ,  A61P9/12

CPC分类号： C12N15/1136 ,  A61K31/4184 ,  A61K31/713 ,  A61P9/12 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/323 ,  C12N2310/33 ,  C12N2310/351

摘要： The present invention relates to methods of inhibiting the expression of an AGT gene in a subject, as well as methods for treating subjects having an AGT-associated disorder, e.g., hypertension, using RNAi agents, e.g., double stranded RNAi agents, targeting the AGT gene. The invention also relates to methods of decreasing blood pressure levels in a subject using such RNAi agents to inhibit expression of an AGT gene.